Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Vose

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Blood|November 26, 2008
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma ProjectWing-yan Au, Dennis D Weisenburger, Tanin Intragumtornchai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2021
<sup>18</sup>F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter studyRyogo Minamimoto, Luis Fayad, Julie Vose, et al.
Blood Cancer Journal|February 14, 2018
Rac1 is a novel therapeutic target in mantle cell lymphomaTian Tian, Chengfeng Bi, Ashley L Hein, et al.
Journal of Oncology Practice|October 25, 2019
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to SponsorsKathryn F Mileham, Caroline Schenkel, Meredith K Chuk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based reviewDenise M Oliansky, Myron Czuczman, Richard I Fisher, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2013
Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?Nicholas A Barber, Fausto R Loberiza, Anamarija M Perry, et al.
British Journal of Haematology|April 15, 2011
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOPMonica Testoni, Ivo Kwee, Timothy C Greiner, et al.
American Journal of Clinical Pathology|December 22, 2010
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy Greiner, et al.
Nature Reviews. Clinical Oncology|December 30, 2016
The landscape of new drugs in lymphomaAnas Younes, Stephen Ansell, Nathan Fowler, et al.
Journal of Global Oncology|September 23, 2018
American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and ActionsGabriel N Hortobagyi, Doug Pyle, Eduardo L Cazap, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Blood|November 26, 2008
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma ProjectWing-yan Au, Dennis D Weisenburger, Tanin Intragumtornchai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2021
<sup>18</sup>F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter studyRyogo Minamimoto, Luis Fayad, Julie Vose, et al.
Blood Cancer Journal|February 14, 2018
Rac1 is a novel therapeutic target in mantle cell lymphomaTian Tian, Chengfeng Bi, Ashley L Hein, et al.
Journal of Oncology Practice|October 25, 2019
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to SponsorsKathryn F Mileham, Caroline Schenkel, Meredith K Chuk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based reviewDenise M Oliansky, Myron Czuczman, Richard I Fisher, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2013
Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?Nicholas A Barber, Fausto R Loberiza, Anamarija M Perry, et al.
British Journal of Haematology|April 15, 2011
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOPMonica Testoni, Ivo Kwee, Timothy C Greiner, et al.
American Journal of Clinical Pathology|December 22, 2010
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy Greiner, et al.
Nature Reviews. Clinical Oncology|December 30, 2016
The landscape of new drugs in lymphomaAnas Younes, Stephen Ansell, Nathan Fowler, et al.
Journal of Global Oncology|September 23, 2018
American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and ActionsGabriel N Hortobagyi, Doug Pyle, Eduardo L Cazap, et al.
Pageof 7